Treating Life-Threatening Bleedings

Dr. Hedner has been active in the field of Thrombosis and Haemostasis for more than 40 years and initiated the idea to use FVIIa as a hemostatic drug when working as a clinician at the University Hospital of Malmö, Lund University, Sweden, in the 1970s. Later, she led the development of recombinant FVIIa when being part of the Department of Research & Development at the Danish pharmaceutical company Novo Nordisk A/S, Bagsværd, Denmark. Dr. Hedner was a physician at the Department of Bleeding Disorders including a Haemophilia Comprehensive Clinic, Malmö University Hospital, University of Lund, Sweden from 1972-1983 . Her research and teaching experience was at the Medical Faculty of Lund University, Sweden and Professor in Clinical Coagulation Research at the University of Gothenburg and at the University of Lund.

• 1. Classical Bleeding Disease (Hemophilia)2. My Encounter With Hemophilia (1959-82)3. The First Years at Novo Nordisk4. The Development of Recombinant FVIIa (rFVIIa) (1985-88)5. The Further Use and Development of rFVIIa (1989-96)6. Legal Issues Regarding the Use of rFVIIa in Hemophilia Patients With Inhibitors7. Treatment With rFVIIa in Malmö (1996-99)8. The Launching and Uses of rFVIIa9. Mechanism of Action and Dosage10. The Continued Development of rFVIIa During the 2000s11. Safety and Health Economy of rFVIIa12. Three Different Descriptions of How rFVIIa Was Developed13. Some Final Remarks